{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:23:16Z","timestamp":1793946196585,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.metabol.2021.154955","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T19:52:48Z","timestamp":1639425168000},"page":"154955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-6894","authenticated-orcid":false,"given":"Zhenqiu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-160X","authenticated-orcid":false,"given":"Xingdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154955_bb0005","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154955_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0015","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2021.154955_bb0020","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cgh.2019.06.036","article-title":"Combined effects of alcohol and metabolic disorders in patients with chronic liver disease","volume":"18","author":"\u00c5berg","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154955_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.01.017","article-title":"On the proposed definition of metabolic-associated fatty liver disease","author":"Wai-Sun Wong","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0040","article-title":"Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease","author":"Wai-Sun Wong","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0045","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0050","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2021.154955_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","author":"Mantovani","year":"2021","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2021.154955_bb0060","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","author":"Kim","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0065","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0070","article-title":"Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China","author":"Wang","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","author":"Simon","year":"2021","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154955_bb0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(18)30288-2","article-title":"Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3\u00b76 million adults in the UK","volume":"6","author":"Bhaskaran","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154955_bb0085","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","author":"Simon","year":"2020","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2021.154955_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10654-018-0438-0","article-title":"Cancer incidence among Finnish people with type 2 diabetes during 1989-2014","volume":"34","author":"Saarela","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.metabol.2021.154955_bb0095","article-title":"The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants","author":"Liu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0100","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154955_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.metabol.2021.154955_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154955_bb0120","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2021.154955_bb0130","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b724 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2021.154955_bb0135","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.metabol.2021.154955_bb0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154955_bb0145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.dld.2015.09.009","article-title":"PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis","volume":"48","author":"Falleti","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2021.154955_bb0155","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s00535-013-0850-x","article-title":"Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene","volume":"49","author":"Tan","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154955_bb0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0165","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154955_bb0170","article-title":"Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: A nationwide cohort study","author":"Park","year":"2021","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2021.154955_bb0175","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154955_bb0180","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154955_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.01.015","article-title":"The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD","author":"Spearman","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.12.035","article-title":"Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists","author":"Fouad","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2020.11.004","article-title":"\u201cDual aetiology fatty liver disease\u201d: a recently proposed term associated with potential pitfalls","volume":"74","author":"Moreno","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0200","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2020-323202","article-title":"From the origin of NASH to the future of metabolic fatty liver disease","volume":"70","author":"Geier","year":"2021","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2021.154955_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12916-020-01848-8","article-title":"Associations of six adiposity-related markers with incidence and mortality from 24 cancers-findings from the UK Biobank prospective cohort study","volume":"19","author":"Parra-Soto","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.metabol.2021.154955_bb0210","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"Bmj."},{"key":"10.1016\/j.metabol.2021.154955_bb0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2012.23","article-title":"The biliary tree\u2013a reservoir of multipotent stem cells","volume":"9","author":"Cardinale","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0220","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.metabol.2021.154955_bb0225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1095\/biolreprod.111.092593","article-title":"Diverse roles for sex hormone-binding globulin in reproduction","volume":"85","author":"Hammond","year":"2011","journal-title":"Biol Reprod"},{"key":"10.1016\/j.metabol.2021.154955_bb0230","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nrc2190","article-title":"Lung cancer in never smokers--a different disease","volume":"7","author":"Sun","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.metabol.2021.154955_bb0235","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/bjc.2013.506","article-title":"Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO)","volume":"109","author":"Pesatori","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.metabol.2021.154955_bb0240","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1073\/pnas.1003585107","article-title":"A feed-forward loop amplifies nutritional regulation of PNPLA3","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2021.154955_bb0245","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154955_bb0250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41395-018-0041-8","article-title":"Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis","volume":"113","author":"Stickel","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154955_bb0255","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154955_bb0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0265","article-title":"Agreement between the prevalence of nonalcoholic fatty liver disease determined by transient elastography and fatty liver indices","author":"Jones","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154955_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154874","article-title":"Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes","volume":"124","author":"Li","year":"2021","journal-title":"Metabolism."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:28:25Z","timestamp":1758428905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521002559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":53,"alternative-id":["S0026049521002559"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154955","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154955"}}